S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Graphite Shortage Story You're Not Being Told (Ad)
Nordstrom's Earnings Beat, A Rally In The Making
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
The Real Problem With "Made in America" Lithium (Ad)
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
How to Invest in Specialty Retail Stores
NASDAQ:AQST

Aquestive Therapeutics (AQST) Stock Forecast, Price & News

$2.31
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$2.25
$2.38
50-Day Range
$0.84
$2.49
52-Week Range
$0.62
$2.69
Volume
485,294 shs
Average Volume
1.01 million shs
Market Capitalization
$129.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.13

Aquestive Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
165.2% Upside
$6.13 Price Target
Short Interest
Healthy
3.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Aquestive Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

1437th out of 1,980 stocks

Pharmaceutical Preparations Industry

721st out of 978 stocks


AQST stock logo

About Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 0.9%
3 Smart Money Stocks to Invest in Today
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
JMP Securities Remains a Buy on Aquestive Therapeutics (AQST)
What Wall Street expects from Aquestive Therapeutics's earnings
See More Headlines

AQST Price History

AQST Company Calendar

Last Earnings
3/08/2023
Today
6/02/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.13
High Stock Price Forecast
$8.50
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+165.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-54,410,000.00
Pretax Margin
-71.16%

Debt

Sales & Book Value

Annual Sales
$47.68 million
Book Value
($1.95) per share

Miscellaneous

Free Float
50,470,000
Market Cap
$129.18 million
Optionable
Not Optionable
Beta
2.72

Key Executives

  • Daniel Barber
    President, Chief Executive Officer & Director
  • Cassie Jung
    Senior Vice President-Operations
  • A. Ernest Toth
    Chief Financial Officer & Senior Vice President
  • A. Mark Schobel
    Chief Technology & Innovation Officer
  • Peter Boyd
    SVP-Human Resources & Communications













AQST Stock - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings
or view top-rated stocks.

What is Aquestive Therapeutics' stock price forecast for 2023?

4 analysts have issued 12 month price targets for Aquestive Therapeutics' stock. Their AQST share price forecasts range from $4.00 to $8.50. On average, they anticipate the company's stock price to reach $6.13 in the next twelve months. This suggests a possible upside of 165.2% from the stock's current price.
View analysts price targets for AQST
or view top-rated stocks among Wall Street analysts.

How have AQST shares performed in 2023?

Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of 2023. Since then, AQST shares have increased by 156.1% and is now trading at $2.31.
View the best growth stocks for 2023 here
.

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our AQST earnings forecast
.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The firm had revenue of $10.68 million for the quarter, compared to analysts' expectations of $9.93 million. During the same period in the previous year, the firm posted ($0.38) EPS.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $42.00 million-$46.00 million, compared to the consensus revenue estimate of $39.06 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vahanian & Associates Financial Planning Inc. (1.29%), Renaissance Technologies LLC (0.93%), Susquehanna International Group LLP (0.21%), HBK Sorce Advisory LLC (0.15%), Financial Advocates Investment Management (0.04%) and Jane Street Group LLC (0.04%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, John T Maxwell, Keith J Kendall, Lori J Braender and Peter E Boyd.
View institutional ownership trends
.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $2.31.

How much money does Aquestive Therapeutics make?

Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $129.18 million and generates $47.68 million in revenue each year. The company earns $-54,410,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How many employees does Aquestive Therapeutics have?

The company employs 157 workers across the globe.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com.

This page (NASDAQ:AQST) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -